Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Awiqli Flextouch. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 1 application for Insulin Icodec (sold as Awiqli Flextouch), first approved Mar 26, 2026, with 1 new use approved and 1 published complete response letter.
First approved: Mar 26, 2026
Applications: 1
New uses approved: 1
Complete response letters: 1
First approved in the EU: May 17, 2024
First approved in Japan: Jun 24, 2024
Approvals in the EU (EMA)
First approved in the EU 22 months before the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
First approved in Japan 21 months before the US. PMDA's English list since 2008, matched by ingredient; see all Japanese approvals
Awiqli, new ingredientDrugs with a new active ingredient indicated for the treatment of diabetes mellitus in cases where insulin therapy is indicated. · Novo Nordisk Pharma Ltd. · Jun 24, 2024 · Review report
Clinical Trials
11 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
NNC0148-0287Facility Inspections, Chemistry, Manufacturing, And Controls (Cmc), Clinical
Unapproved
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA